Perceptive Advisors’s ImmunityBio IBRX Stock Holding History

Perceptive Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,221,734	Closed	-$3.13M	–	96
2024 Q4	$3.13M	Buy	+1,221,734	New	+$5.09M	0.09%	81
2024 Q2	–	Sell	-1,052,887	Closed	-$5.65M	–	119
2024 Q1	$5.65M	Buy	+1,052,887	New	+$4.77M	0.1%	84
2016 Q1	–	Sell	-10,000	Closed	-$173K	–	178
2015 Q4	$173K	Buy	+10,000	New	+$148K	0.01%	135

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Perceptive Advisors's IBRX Position: Q1 2025 in Review

Perceptive Advisors sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 1,221,734 shares — an estimated $3.13M sold.

Perceptive Advisors first reported a position in IBRX in Q4 2015 and held it in 3 quarters. The position peaked at $5.65M in Q1 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

Perceptive Advisors reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
Perceptive Advisors sold 1,221,734 ImmunityBio shares in Q1 2025, an estimated $3.13M.
Perceptive Advisors first reported a position in ImmunityBio in Q4 2015 and held it in 3 quarters.
Perceptive Advisors's ImmunityBio position peaked at $5.65M in Q1 2024.
210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.